Showing results (31-40 of 71) with videos related to
Sort By:
Pageof 8
Expert Review of Pharmacoeconomics & Outcomes Research|January 17, 2017
The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventionsJ Schepers, J Plaete, I De Bourdeaudhuij, et al.Journal of Psychiatric and Mental Health Nursing|July 14, 2011
Perceptions of mental health nurses and patients about health promotion in mental health care: a literature reviewN Verhaeghe, J De Maeseneer, L Maes, et al.Acta Clinica Belgica|February 21, 2008
Long-term outcome after acute kidney injury in critically-ill patientsS Oeyen, D Vandijck, D Benoit, et al.International Journal of Clinical Practice|August 31, 2006
Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluationL Annemans, M Lamotte, M Kubin, et al.Acta Clinica Belgica|February 21, 2008
Acute kidney injury, length of stay, and costs in patients hospitalized in the intensive care unitD M Vandijck, S Oeyen, J M Decruyenaere, et al.Acta Clinica Belgica|March 21, 2008
Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysisL Annemans, E Van Cutsem, Y Humblet, et al.Revue Medicale De Liege|May 23, 2012
[New European guidelines for the management of dyslipidaemia in cardiovascular prevention]O S Descamps, G De Backer, L Annemans, et al.Acta Clinica Belgica|August 22, 2008
A cost-utility analysis of pregabalin in the management of peripheral neuropathic painL Annemans, K Caekelbergh, B Morlion, et al.International Journal of Hematology|October 7, 2005
Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in KoreaK Moeremans, L Annemans, Ji-So Ryu, et al.Revue Medicale De Liege|June 8, 2012
[How I treat ... dyslipidemia according to the cardiovascular risk profile]O S Descamps, A J Scheen, G De Backer, et al.Pageof 8